Cargando…

Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy

AIMS: The role of necroptosis in dilated cardiomyopathy (DCM) remains unclear. Here, we examined whether phosphorylation of mixed lineage kinase domain‐like protein (MLKL), an indispensable event for execution of necroptosis, is associated with the progression of DCM. METHODS AND RESULTS: Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Yugo, Yano, Toshiyuki, Kanamori, Hiromitsu, Nagahara, Daigo, Muranaka, Atsuko, Kouzu, Hidemichi, Mochizuki, Atsushi, Koyama, Masayuki, Nagano, Nobutaka, Fujito, Takefumi, Nishikawa, Ryo, Kamiyama, Naoyuki, Tanaka, Marenao, Kuno, Atsushi, Tanno, Masaya, Miura, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715765/
https://www.ncbi.nlm.nih.gov/pubmed/35851586
http://dx.doi.org/10.1002/ehf2.14059
_version_ 1784842529147977728
author Fujita, Yugo
Yano, Toshiyuki
Kanamori, Hiromitsu
Nagahara, Daigo
Muranaka, Atsuko
Kouzu, Hidemichi
Mochizuki, Atsushi
Koyama, Masayuki
Nagano, Nobutaka
Fujito, Takefumi
Nishikawa, Ryo
Kamiyama, Naoyuki
Tanaka, Marenao
Kuno, Atsushi
Tanno, Masaya
Miura, Tetsuji
author_facet Fujita, Yugo
Yano, Toshiyuki
Kanamori, Hiromitsu
Nagahara, Daigo
Muranaka, Atsuko
Kouzu, Hidemichi
Mochizuki, Atsushi
Koyama, Masayuki
Nagano, Nobutaka
Fujito, Takefumi
Nishikawa, Ryo
Kamiyama, Naoyuki
Tanaka, Marenao
Kuno, Atsushi
Tanno, Masaya
Miura, Tetsuji
author_sort Fujita, Yugo
collection PubMed
description AIMS: The role of necroptosis in dilated cardiomyopathy (DCM) remains unclear. Here, we examined whether phosphorylation of mixed lineage kinase domain‐like protein (MLKL), an indispensable event for execution of necroptosis, is associated with the progression of DCM. METHODS AND RESULTS: Patients with DCM (n = 56, 56 ± 15 years of age; 68% male) were enrolled for immunohistochemical analyses of biopsies. Adverse events were defined as a composite of death or admission for heart failure or ventricular arrhythmia. Compared with the normal myocardium, increased signals of MLKL phosphorylation were detected in the nuclei, cytoplasm, and intercalated discs of cardiomyocytes in biopsy samples from DCM patients. The phosphorylated MLKL (p‐MLKL) signal was increased in enlarged nuclei or nuclei with bizarre shapes in hypertrophied cardiomyocytes. Nuclear p‐MLKL level was correlated negatively with septal peak myocardial velocity during early diastole (r = −0.327, P = 0.019) and was correlated positively with tricuspid regurgitation pressure gradient (r = 0.339, P = 0.023), while p‐MLKL level in intercalated discs was negatively correlated with mean left ventricular wall thickness (r = −0.360, P = 0.014). During a median follow‐up period of 3.5 years, 10 patients (18%) had adverse events. To examine the difference in event rates according to p‐MLKL expression levels, patients were divided into two groups by using the median value of nuclear p‐MLKL or intercalated disc p‐MLKL. A group with high nuclear p‐MLKL level (H‐nucMLKL group) had a higher adverse event rate than did a group with low nuclear p‐MLKL level (L‐nucMLKL group) (32% vs. 4%, P = 0.012), and Kaplan–Meier survival curves showed that the adverse event‐free survival rate was lower in the H‐nucMLKL group than in the L‐nucMLKL group (P = 0.019 by the log‐rank test). Such differences were not detected between groups divided by a median value of intercalated disc p‐MLKL. In δ‐sarcoglycan‐deficient (Sgcd(−/−)) mice, a model of DCM, total p‐MLKL and nuclear p‐MLKL levels were higher than in wild‐type mice. CONCLUSION: The results suggest that increased localization of nuclear p‐MLKL in cardiomyocytes is associated with left ventricular diastolic dysfunction and future adverse events in DCM.
format Online
Article
Text
id pubmed-9715765
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97157652022-12-05 Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy Fujita, Yugo Yano, Toshiyuki Kanamori, Hiromitsu Nagahara, Daigo Muranaka, Atsuko Kouzu, Hidemichi Mochizuki, Atsushi Koyama, Masayuki Nagano, Nobutaka Fujito, Takefumi Nishikawa, Ryo Kamiyama, Naoyuki Tanaka, Marenao Kuno, Atsushi Tanno, Masaya Miura, Tetsuji ESC Heart Fail Original Articles AIMS: The role of necroptosis in dilated cardiomyopathy (DCM) remains unclear. Here, we examined whether phosphorylation of mixed lineage kinase domain‐like protein (MLKL), an indispensable event for execution of necroptosis, is associated with the progression of DCM. METHODS AND RESULTS: Patients with DCM (n = 56, 56 ± 15 years of age; 68% male) were enrolled for immunohistochemical analyses of biopsies. Adverse events were defined as a composite of death or admission for heart failure or ventricular arrhythmia. Compared with the normal myocardium, increased signals of MLKL phosphorylation were detected in the nuclei, cytoplasm, and intercalated discs of cardiomyocytes in biopsy samples from DCM patients. The phosphorylated MLKL (p‐MLKL) signal was increased in enlarged nuclei or nuclei with bizarre shapes in hypertrophied cardiomyocytes. Nuclear p‐MLKL level was correlated negatively with septal peak myocardial velocity during early diastole (r = −0.327, P = 0.019) and was correlated positively with tricuspid regurgitation pressure gradient (r = 0.339, P = 0.023), while p‐MLKL level in intercalated discs was negatively correlated with mean left ventricular wall thickness (r = −0.360, P = 0.014). During a median follow‐up period of 3.5 years, 10 patients (18%) had adverse events. To examine the difference in event rates according to p‐MLKL expression levels, patients were divided into two groups by using the median value of nuclear p‐MLKL or intercalated disc p‐MLKL. A group with high nuclear p‐MLKL level (H‐nucMLKL group) had a higher adverse event rate than did a group with low nuclear p‐MLKL level (L‐nucMLKL group) (32% vs. 4%, P = 0.012), and Kaplan–Meier survival curves showed that the adverse event‐free survival rate was lower in the H‐nucMLKL group than in the L‐nucMLKL group (P = 0.019 by the log‐rank test). Such differences were not detected between groups divided by a median value of intercalated disc p‐MLKL. In δ‐sarcoglycan‐deficient (Sgcd(−/−)) mice, a model of DCM, total p‐MLKL and nuclear p‐MLKL levels were higher than in wild‐type mice. CONCLUSION: The results suggest that increased localization of nuclear p‐MLKL in cardiomyocytes is associated with left ventricular diastolic dysfunction and future adverse events in DCM. John Wiley and Sons Inc. 2022-07-18 /pmc/articles/PMC9715765/ /pubmed/35851586 http://dx.doi.org/10.1002/ehf2.14059 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Fujita, Yugo
Yano, Toshiyuki
Kanamori, Hiromitsu
Nagahara, Daigo
Muranaka, Atsuko
Kouzu, Hidemichi
Mochizuki, Atsushi
Koyama, Masayuki
Nagano, Nobutaka
Fujito, Takefumi
Nishikawa, Ryo
Kamiyama, Naoyuki
Tanaka, Marenao
Kuno, Atsushi
Tanno, Masaya
Miura, Tetsuji
Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy
title Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy
title_full Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy
title_fullStr Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy
title_full_unstemmed Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy
title_short Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy
title_sort enhanced nuclear localization of phosphorylated mlkl predicts adverse events in patients with dilated cardiomyopathy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715765/
https://www.ncbi.nlm.nih.gov/pubmed/35851586
http://dx.doi.org/10.1002/ehf2.14059
work_keys_str_mv AT fujitayugo enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT yanotoshiyuki enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT kanamorihiromitsu enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT nagaharadaigo enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT muranakaatsuko enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT kouzuhidemichi enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT mochizukiatsushi enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT koyamamasayuki enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT naganonobutaka enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT fujitotakefumi enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT nishikawaryo enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT kamiyamanaoyuki enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT tanakamarenao enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT kunoatsushi enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT tannomasaya enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy
AT miuratetsuji enhancednuclearlocalizationofphosphorylatedmlklpredictsadverseeventsinpatientswithdilatedcardiomyopathy